BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting

被引：3

作者：

Zheng, Huijian ^{[1
]}

Xian, Huajian ^{[2
]}

Zhang, Wenjie ^{[1
]}

Lu, Chaoqun ^{[2
]}

Pan, Renyao ^{[1
]}

Liu, Han ^{[2
]}

Xu, Zhenshu ^{[1
]}

机构：

[1] Fujian Med Univ, Union Hosp, Fujian Inst Hematol, Fujian Prov Key Lab Hematol, 29 Xinquan Rd, Fuzhou 350001, Peoples R China

[2] Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai, Shanghai Inst Hematol,State Key Lab Med Genom,Sch, Shanghai 200025, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2025年 / 18卷 / 01期

基金：

中国国家自然科学基金;

关键词：

BCMA-targeted therapies; Multiple myeloma; ASH; 2024;

D O I：

10.1186/s13045-025-01675-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting.

引用

页数：4

共 11 条

[1] Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide [J].

Beksac, Meral ;

Garcia, Esther Gonzalez ;

Delimpasi, Sosana ;

Robak, Pawel ;

Karunanithi, Kamaraj ;

De Arriba, Felipe ;

Radocha, Jakub ;

Kim, Kihyun ;

Voloshin, Sergey ;

Zherebtsova, Vera ;

Osipov, Iurii ;

Mateos, Maria-Victoria ;

Zafar, Syed F. ;

Pour, Ludek ;

Spicka, Ivan ;

Suzuki, Kazuhito ;

Du, Xin ;

Wilkes, Jodie ;

Maroj, Brijesh ;

Morris, Kristin ;

Ma, Jie ;

Polinkovsky, Margaret ;

Wang, Zhaohui ;

Zhou, Xiaoou L. ;

Fulci, Giulia ;

Sule, Neal ;

Kremer, Brandon ;

Opalinska, Joanna ;

Trudel, Suzanne ;

Dimopoulos, Meletios A. .

BLOOD, 2024, 144 :4731-4733

[2]

Bishop MR, 2024, Blood, V144, P4825

[3] Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies [J].

D'Souza, Anita ;

Costa, Luciano J. ;

San-Miguel, Jesus F. ;

Berdeja, Jesus G. ;

Giles, Daniel Morillo ;

Touzeau, Cyrille ;

Mckay, John ;

Dholaria, Bhagirathbhai ;

Martin, Thomas G. ;

Perrot, Aurore ;

Oriol, Albert ;

Balari, Anna Sureda ;

Prior, Thomas ;

Ghosh, Debopriya ;

Kang, Lijuan ;

Larsen, Julie S. ;

Ludlage, Hein ;

Vandenberk, Lien ;

Chen, Lingling ;

Koster, Bas ;

Sun, Weili ;

Kobos, Rachel ;

Searle, Emma ;

Matous, Jeffrey, V ;

Chari, Ajai ;

Kampfenkel, Tobias .

BLOOD, 2024, 144 :498-498

[4] Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial [J].

Freeman, Ciara Louise ;

Dhakal, Binod ;

Kaur, Gurbakhash ;

Maziarz, Richard T. ;

Callander, Natalie ;

Sperling, Adam S. ;

Schinke, Carolina ;

Jakubowiak, Andrzej J. ;

Biran, Noa ;

Sborov, Douglas W. ;

Varga, Cindy ;

Deol, Abhinav ;

Kanate, Abraham S. ;

Kocoglu, Mehmet Hakan ;

Solh, Melhem M. ;

Banerjee, Kamalika ;

Chan, Rebecca ;

Nahas, Myrna ;

Kostic, Ana ;

Granados, Enrique ;

Jackson, Carolyn ;

Heery, Christopher R. ;

Welliver, Tim ;

Patel, Krina K. ;

Frigault, Matthew .

BLOOD, 2024, 144 :1031-1033

[5]

Hungria V., 2024, Blood, V144, P10

[6] Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial [J].

Hungria, Vania ;

Robak, Pawel ;

Hus, Marek ;

Zherebtsova, Vera ;

Ward, Christopher ;

Ho, Phoebe Joy ;

Hajek, Roman ;

Kim, Kihyun ;

Grosicki, Sebastian ;

Sia, Hanlon ;

Bryant, Adam ;

Lacerda, Marcelo Pitombeira de ;

Martinez, Gracia Aparecida ;

Balari, Anna Maria Sureda ;

Sandhu, Irwindeep ;

Cerchione, Claudio ;

Ganly, Peter ;

Dimopoulos, Meletios ;

Fu, Chengcheng ;

Garg, Mamta ;

Abdallah, Al-Ola ;

Gatt, Moshe E. ;

Oriol, Albert ;

Cavo, Michele ;

Rifkin, Robert ;

Fujisaki, Tomoaki ;

Mielnik, Micha ;

Pirooz, Nick ;

Lee, Joe ;

Mckeown, Astrid ;

Rogers, Rachel ;

Baig, Hena ;

Eccersley, Lydia ;

Roy-Ghanta, Sumita ;

Mateos, Maria Victoria .

BLOOD, 2024, 144 :772-774

[7]

Popat R, 2024, Blood, V144, P1032, DOI [10.1182/blood, DOI 10.1182/BLOOD]

[8] Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-(( (MajesTEC-5) Trial [J].

Raab, Marc S. ;

Weinhold, Niels ;

Kortuem, K. Martin ;

Kroenke, Jan ;

Podola, Lilli ;

Bertsch, Uta ;

Frenking, Jan H. ;

Mersi, Julia ;

Huhn, Stefanie ;

Hundemer, Michael ;

Mechtersheimer, Gunhild ;

Fenk, Roland ;

Weisel, Katja C. ;

Schub, Natalie ;

Bassermann, Florian ;

Engelhardt, Monika ;

Teipel, Raphael ;

Hanel, Mathias ;

Salwender, Hans ;

Koster, Bas ;

Ershova, Elena ;

Sakabedoyan, Caline ;

Barrott, Isobel ;

Balogh, Agnes ;

Vara, Sanjay ;

Kampfenkel, Tobias ;

Goldschmidt, Hartmut ;

Einsele, Hermann ;

Rasche, Leo .

BLOOD, 2024, 144 :493-495

[9]

Usmani SZ., 2024, Updated Interim Anal Blood, V144, P497

[10] BCMA-targeted immunotherapy for multiple myeloma [J].

Yu, Bo ;

Jiang, Tianbo ;

Liu, Delong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)

← 1 2 →